Literature DB >> 20329580

[Probiotics in acute pancreatitis--a randomised, placebo-controlled, double-blind study].

J Lata1, J Juránková, O Stibůrek, V Príbramská, M Senkyrík, T Vanásek.   

Abstract

INTRODUCTION: Infections accompanying pancreatitis, particularly pancreatic necroses, represent a serious complication associated with worsening of the disease prognosis. The aim of our study was to explore whether this complication could be prevented by administering a probiotic.
METHODS: The probiotic was administered to 7 patients and placebo to 15. The study was discontinued early following the release of the Propatria study results.
RESULTS: There was no death in our patient sample and there was no difference between the two groups in microbial colonisation or the length of hospitalization. However, a reduction in endotoxin levels on day 7 and 10 of the hospitalization was observed in the probiotic-treated group.
CONCLUSION: Based on the current knowledge, administration of probiotics in this indication is contraindicated. Nonetheless, reduction in endotoxin levels suggests a positive effect of probiotics on bacterial translocation, the importance of which should be evaluated in the future.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20329580

Source DB:  PubMed          Journal:  Vnitr Lek        ISSN: 0042-773X


  3 in total

Review 1.  Pharmacological interventions for acute pancreatitis.

Authors:  Elisabetta Moggia; Rahul Koti; Ajay P Belgaumkar; Federico Fazio; Stephen P Pereira; Brian R Davidson; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-04-21

Review 2.  Recent Advances on Nutrition in Treatment of Acute Pancreatitis.

Authors:  Li-Long Pan; Jiahong Li; Muhammad Shamoon; Madhav Bhatia; Jia Sun
Journal:  Front Immunol       Date:  2017-06-30       Impact factor: 7.561

3.  Supplemented Use of Pre-, Pro-, and Synbiotics in Severe Acute Pancreatitis: An Updated Systematic Review and Meta-Analysis of 13 Randomized Controlled Trials.

Authors:  Xu Tian; Yuan-Ping Pi; Xiao-Ling Liu; Hui Chen; Wei-Qing Chen
Journal:  Front Pharmacol       Date:  2018-06-28       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.